Compare Quest Diagnostics Inc (DGX) vs Tripadvisor Inc Common Stock (TRIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Tripadvisor Inc Common Stock — how do they compare? Quest Diagnostics Inc trades at $237.87 (market cap $26.21B), while Tripadvisor Inc Common Stock trades at $10.59 (market cap $1.28B). The key difference: Quest Diagnostics Inc is far larger — about 20.5× Tripadvisor Inc Common Stock's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while Tripadvisor Inc Common Stock pays none. Which is the better fit depends on your goals.
| DGX | TRIP | |
|---|---|---|
Market Cap | $26.21B | $1.28B |
Sector | Health | Consumer Cyclical |
52-Week High | $238.50 | $19.14 |
52-Week Low | $173.49 | $9.24 |
Enterprise Value | $31.97B | $1.33B |
Dividend Yield | 1.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $237.63, down slightly by 0.3% today, but maintains strong momentum with three consecutive quarterly earnings beats and a raised 2026 outlook. The stock shows bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid revenue growth to $11.04 billion in 2025 and improving profit margins. Recent news highlights surging testing demand and AI implementation driving operational efficiency.
DGX presents a favorable investment case with analyst consensus price target of $249.50 offering 5% upside potential. Strong testing demand, strategic partnerships, and earnings momentum support growth, though elevated debt levels and margin pressures from lower-margin deals pose moderate risks. The stock's current valuation at 25.21 P/E appears reasonable given growth prospects.
Tripadvisor (TRIP) trades at $10.78, flat on the day, with a bearish technical signal but bullish oscillators. The company reported Q2 2026 EPS of $0.35, missing estimates, though revenue reached $1.89B in 2025 with a net income margin of 2.11%. Recent news highlights competitive pressures from AI travel tools and the pending $700M sale of TheFork to American Express, providing a cash infusion.
Outlook remains mixed; the stock is undervalued on P/S (0.72) but carries a high P/E (127.18). Risks include stiff competition and earnings misses, yet analyst consensus targets $13.29, suggesting 23% upside. Investor sentiment is cautious, with 62.5% hold ratings, but Viator's U.S. leadership offers a growth avenue amid challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Tripadvisor Inc Common Stock
TripAdvisor is the world's leading travel metasearch company. The website offers 1 billion reviews and information on about 8 million accommodations, restaurants, experiences, airlines, and cruises. In 2021, 74% of revenue came from the company's core segment, which includes hotel revenue generated through advertising on its metasearch platform. Viator, its experiences brand, was 20% of sales in 2021, and TheFork, its dining brand, represented 9% of revenue (about 3% of sales were intersegment, which are eliminated from consolidated revenue).
Read more on TRIP →
